{"id":227773,"date":"2025-12-24T14:10:25","date_gmt":"2025-12-24T20:10:25","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/adjuvant-chemotherapy-for-hr-positive-erbb2-negative-breast-cancer"},"modified":"2025-12-24T14:10:25","modified_gmt":"2025-12-24T20:10:25","slug":"adjuvant-chemotherapy-for-hr-positive-erbb2-negative-breast-cancer","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/adjuvant-chemotherapy-for-hr-positive-erbb2-negative-breast-cancer","title":{"rendered":"Adjuvant Chemotherapy for HR-Positive, ERBB2-Negative Breast Cancer"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/adjuvant-chemotherapy-for-hr-positive-erbb2-negative-breast-cancer.jpg\"><\/a><\/p>\n<p>Adjuvant chemotherapy use almost doubled in premenopausal patients with node-positive tumors and with a low to intermediate genomic risk from 2019 to 2022 but decreased for patients with node-negative disease.<\/p>\n<hr>\n<p>Question What are the patterns of adjuvant chemotherapy use for early-stage hormone receptor (HR)\u2013positive, <i>ERBB2-<\/i>negative breast cancer by genomic risk and nodal status?<\/p>\n<p><strong>Findings<\/strong> In this cohort study of 504 937 women, adjuvant chemotherapy use nearly doubled in premenopausal patients with node-positive tumors and low or intermediate 21-gene recurrence score from 2019 to 2022 but decreased for women with node-negative disease.<\/p>\n<p><strong>Meaning<\/strong> The findings highlight the variability in genomic assay use to inform adjuvant systemic therapy recommendations in HR-positive, <i>ERBB2<\/i>-negative breast cancer.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Adjuvant chemotherapy use almost doubled in premenopausal patients with node-positive tumors and with a low to intermediate genomic risk from 2019 to 2022 but decreased for patients with node-negative disease. Question What are the patterns of adjuvant chemotherapy use for early-stage hormone receptor (HR)\u2013positive, ERBB2-negative breast cancer by genomic risk and nodal status? Findings In [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-227773","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=227773"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227773\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=227773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=227773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=227773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}